Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexedPasi A. Jänne, David Planchard, Kunihiko Kobayashi et al.|Cancer Research|2024Cited by 25
A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3β Phosphorylation Site and Is Associated with Altered Tamoxifen Response in BoneRyan J. Hartmaier, Steffi Oesterreich, Andreas S. Richter et al.|Molecular Endocrinology|2011Cited by 20
Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD studyRyan J. Hartmaier, Zofia Piotrowska, Aleksandra Markovets et al.|Cancer Research|2022Cited by 12
Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).Benjamin Levy, Myung‐Ju Ahn, Adrian G. Sacher et al.|Journal of Clinical Oncology|2025Cited by 4
P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line OsimertinibB.C. Cho, Helena A. Yu, Zofia Piotrowska et al.|Journal of Thoracic Oncology|2021Cited by 3